Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

European Journal of Cancer

Volumn 39, Issue 16, 2003, Pages 2310-2317

  Thurlimann B ^a   Robertson, J F R ^b   Nabholtz, J M ^c   Buzdar, A ^d   Bonneterre, J ^e  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CENTRE OSCAR LAMBRET   (France)

Author keywords

Advanced breast cancer; Anastrozole; First line; Postmenopausal; Second line; Sequencing; Tamoxifen

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 17444453765     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00602-6     Document Type: Article

References (20)

1. Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
2. Buzdar A.U., Jonat W., Howell A.et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer. 83:1998;1142-1152.
3. Dombernowsky P., Smith I., Falkson G.et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer. double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J. Clin. Oncol. 16:1998;453-461.
4. Bonneterre J., Thürlimann B., Robertson J.F.R.et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (Tamoxifen or Arimidex™ Randomised Group Efficacy and Tolerability) study. J. Clin. Oncol. 18:2000;3748-3757.
5. Nabholtz J.M., Buzdar A., Pollak M.et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. results of a North American multicenter randomized trial J. Clin. Oncol. 18:2000;3758-3776.
6. Bonneterre J., Buzdar A., Nabholtz J.M.et al. Anastrozole (Arimidex) is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast cancer. results of two randomized trials designed for combined analysis Cancer. 92:2001;2247-2258.
7. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thürlimann B. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003, 39, 1684-1689.
8. Kaufmann M., Bajetta E., Dirix L.-Y.et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer. results of a phase III randomized double-blind trial J. Clin. Oncol. 18:2000;1399-1411.
9. Mourisden H., Gershanovich M., Sun Y.et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. results of a phase III study of the International Letrozole Breast Cancer Group J. Clin. Oncol. 19:2001;2596-2606.
10. Thürlimann B., Beretta K., Bacchi M.et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann. Oncol. 7:1996;471-479.
11. Murray R., Pitt P. Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat. 35:1995;249-253.
12. Thürlimann B., Paridaens R., Serin D.et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide. a phase II multicentre multinational study Eur. J. Cancer. 33:1997;1767-1773.
13. Harper-Wynne C., Coombes R.C. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur. J. Cancer. 35:1999;744-746.
14. Lonning P.E., Bajetta E., Murray R.et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. a phase II trial J. Clin. Oncol. 18:2000;2234-2244.
15. Boccardo F., Rubagotti A., Amoroso D.et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients. results of an Italian cooperative study J. Clin. Oncol. 19:2001;4209-4215.
16. Goss P.E. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin. Cancer Res. 7(Suppl. 12):2001;4397s-4401s. [discussion 4411s-4412s].
17. Coombes R.C., Bliss J.M., Gibson L.J.et al. The Intergroup Exemestane Study (IES) - design and characteristics. Proc ASCO. 21:2002;44b. (abstr 1986).
18. International Breast Cancer Study Group IBCSG 18-98. Adjuvant therapy for postmenopausal patients with operable breast cancer who have estrogen receptor or progesteron receptor positive tumors. Tamoxifen vs letrozole vs tamoxifen followed by letrozole. Available from: http://www.ibcsg.org/pub_trials_open.shtml.
19. Milla-Santos A, Milla L, Portella J, et al. Anastrozole vs tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a double-blind, prospective, randomized, phase III study. Am J Clin Oncol 2003, 26, 317-322.
20. Thürlimann B, Hess D, Koeberle D, et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind crossover SAKK trial 21/95 - a sub-study of Anastrozole Trial 0027. Proc 25th Annual SABCS, Breast Cancer Res Treat 2002, 76(Suppl. 1) (abstr 255). Available from: http://www.abstracts-on-line.com/abstracts/BCS/ [accessed January 2003].